Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Lamarca

Showing results (171-180 of 201) with videos related to

Pageof 21
Sort By:
Gut|May 17, 2022
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directionsRocio I R Macias, Vincenzo Cardinale, Timothy J Kendall, et al.
Cancers|May 28, 2022
Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA RegistryLynn E Nooijen, Jesus M Banales, Marieke T de Boer, et al.
The Lancet. Oncology|April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trialAngela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Frontiers in Endocrinology|June 24, 2021
The Impact of <sup>68</sup>Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine TumoursDaniel J Cuthbertson, Jorge Barriuso, Angela Lamarca, et al.
The Lancet Regional Health. Europe|May 19, 2025
Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [The Lancet Regional Health - Europe, volume 50, March 2025, 101170]Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
The Lancet. Oncology|July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' replyAngela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
The Lancet Regional Health. Europe|March 17, 2025
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across EuropeLorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 1, 2020
Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective AnalysisStefan Buettner, Arthur J A T Braat, Georgios Antonios Margonis, et al.
Journal of Neuroendocrinology|December 14, 2023
Use and perceived utility of [<sup>18</sup> F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.
Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.
Pageof 21

Showing results (171-180 of 201) with videos related to

Sort By:
Pageof 21
Gut|May 17, 2022
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directionsRocio I R Macias, Vincenzo Cardinale, Timothy J Kendall, et al.
Cancers|May 28, 2022
Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA RegistryLynn E Nooijen, Jesus M Banales, Marieke T de Boer, et al.
The Lancet. Oncology|April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trialAngela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Frontiers in Endocrinology|June 24, 2021
The Impact of <sup>68</sup>Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine TumoursDaniel J Cuthbertson, Jorge Barriuso, Angela Lamarca, et al.
The Lancet Regional Health. Europe|May 19, 2025
Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [The Lancet Regional Health - Europe, volume 50, March 2025, 101170]Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
The Lancet. Oncology|July 1, 2021
Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' replyAngela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
The Lancet Regional Health. Europe|March 17, 2025
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across EuropeLorenza Rimassa, Angela Lamarca, Grainne M O'Kane, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 1, 2020
Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective AnalysisStefan Buettner, Arthur J A T Braat, Georgios Antonios Margonis, et al.
Journal of Neuroendocrinology|December 14, 2023
Use and perceived utility of [<sup>18</sup> F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.
Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.
Pageof 21